Pages that link to "Q46891229"

The following pages link to Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. (Q46891229):

Displaying 8 items.

• Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV (Q24202180) (← links)
• The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children (Q33788780) (← links)
• Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC) (Q35060232) (← links)
• Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment (Q35895763) (← links)
• Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents (Q37154669) (← links)
• Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents (Q37925813) (← links)
• Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis (Q38723580) (← links)
• Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants (Q44317274) (← links)